{
    "clinical_study": {
        "@rank": "3382", 
        "brief_summary": {
            "textblock": "The primary objective of the study is to evaluate the effectiveness of l-leucovorin in\n      preventing toxicity from high dose trimethoprim / sulfamethoxazole (TMP / SMX) used as a\n      therapy for Pneumocystis carinii pneumonia (PCP) in patients with AIDS."
        }, 
        "brief_title": "A Randomized, Double-Blind, Placebo Controlled Study of l-Leucovorin in Combination With Trimethoprim / Sulfamethoxazole in the Therapy of Pneumocystis Carinii Pneumonia in Patients With the Acquired Immunodeficiency Syndrome", 
        "condition": [
            "Pneumonia, Pneumocystis Carinii", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Immunologic Deficiency Syndromes", 
                "Pneumonia", 
                "Pneumonia, Pneumocystis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have the following:\n\n          -  Diagnosis of PCP.\n\n          -  Fit the CDC definition of AIDS.\n\n          -  Be receiving intravenous or oral trimethoprim / sulfamethoxazole (Bactrim, Septra) in\n             doses of = or > 15mg/kg/day of the trimethoprim component.\n\n          -  Be receiving  = or < 48 hours of trimethoprim / sulfamethoxazole (TMP / SMX) prior to\n             randomization.\n\n          -  Must sign informed consent in accordance with FDA guidelines.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Cannot take oral medications.\n\n          -  Require continued administration of anticonvulsant agents such as phenytoin,\n             phenobarbital or primidone.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Continued administration of anticonvulsant agents such as phenytoin, phenobarbital or\n             primidone.\n\n        Patients with the following are excluded:\n\n          -  Cannot take oral medications.\n\n          -  Require continued administration of anticonvulsant agents such as phenytoin,\n             phenobarbital or primidone.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  > 48 hours of trimethoprim / sulfamethoxazole prior to randomization."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002002", 
            "org_study_id": "056A", 
            "secondary_id": "76-9"
        }, 
        "intervention": [
            {
                "intervention_name": "Trimethoprim", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Sulfamethoxazole", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Leucovorin calcium", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Leucovorin", 
                "Levoleucovorin", 
                "Sulfamethoxazole", 
                "Trimethoprim", 
                "Trimethoprim-Sulfamethoxazole Combination"
            ]
        }, 
        "keyword": [
            "Trimethoprim-Sulfamethoxazole Combination", 
            "AIDS-Related Opportunistic Infections", 
            "Pneumonia, Pneumocystis carinii", 
            "Acquired Immunodeficiency Syndrome"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "941102859"
                }, 
                "name": "San Francisco Gen Hosp"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Randomized, Double-Blind, Placebo Controlled Study of l-Leucovorin in Combination With Trimethoprim / Sulfamethoxazole in the Therapy of Pneumocystis Carinii Pneumonia in Patients With the Acquired Immunodeficiency Syndrome", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": {
            "PMID": "7930736", 
            "citation": "Safrin S, Lee BL, Sande MA. Adjunctive folinic acid with trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death. J Infect Dis. 1994 Oct;170(4):912-7."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002002"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lederle Laboratories", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 1992"
    }, 
    "geocoordinates": {
        "San Francisco Gen Hosp": "37.775 -122.419"
    }
}